Dr MASSARD Vincent

Fiche personne

Coordonnées

Institut de cancérologie de Lorraine
6 avenue de Bourgogne
54511 VANDOEUVRE-LES-NANCY Cedex

03 83 59 84 61

Territoire

Lorraine

Statut

Hospitalier

Affiliation

Institut de cancérologie de Lorraine (ICL)

Recherche

Expertises :
- Oncologie médicale

Projets

Biopsie liquide pour l'évaluation de l'hétérogénéité clonale et de l'évolution tumorale chez les patientes atteints d'un cancer du sein hormono-dépendant traité par anti-CDK4/6 (CICLADES-CE)

2020 - Porteur du projet : Pr HARLE Alexandre - Partenaire : Pr MERLIN Jean-Louis , Dr MASSARD Vincent

Publications

Real-World Outcomes of [Lu]Lu-PSMA-617 in the French Early-Access Program for Patients with Metastatic Castration-Resistant Prostate Cancer.

Bailly C, Vija L, Somme F, Massard V, Barthélémy P, Giraudet AL, Godbert Y, Fléchon A, Girault S, Abadie-Lacourtoisie S, Viala C, Douillet A, Chêne S, Olivier P, Roubaud G

J Nucl Med. 2026 08 6;:

Characteristics, treatment and survival of older patients with metastatic triple negative breast cancer from the ESME mBC real-world national cohort: a comparison with younger women.

Mairé M, Bouteiller F, Chakiba C, Jacot W, Geiss R, Ung M, Goncalves A, Frenel JS, Bailleux C, Perrin C, Massard V, Mailliez A, Jouannaud C, Cherifi F, Petit T, Terret C, Viansone A, Bosquet L, Galvin A

Breast. 2026 05 22;88:104816

Characteristics and outcomes of patients with HER2-negative metastatic breast cancers with low expression of estrogen and progesterone receptors in the multicenter ESME cohort.

Alexandre M, Teruel E, Dalenc F, de la Motte Rouge T, Brain E, Massard V, Arnedos M, Mailliez A, Ferrero JM, Bachelot T, Desmoulins I, Mouret-Reynier MA, Levy C, Gonçalves A, Berghian A, Petit T, Frenel JS, Martin AL, Grinda T, Jacot W

Breast. 2026 05 18;88:104815

BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancer.

Guinel T, Lusque A, Mailliez A, Massard V, Jacot W, Guiu S, de la Motte Rouge T, Brain E, Desmoulins I, Arnedos M, Bailleux C, Goncalves A, Levy C, Bachelot T, Bosquet L, Delaloge S, Frénel JS

Breast. 2026 02 16;86:104739

Sarcopenia Predicts Mortality in Bladder Cancer with Neoadjuvant Chemotherapy: A Multicenter Study.

Pitout A, Mazeaud C, Blondeau A, Salleron J, Massard V, Lambert A

Cancers (Basel). 2026 01 11;18(2):

Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohort.

Bouteiller F, Gourgou S, Bringuier M, Galvin A, Mailliez A, Bertrand N, Hung M, Frenel JS, Massard V, Bachelot T, Pflumio C, Gonçalves A, Levy C, Bosquet L, Jacot W, Delaloge S, Grinda T, Bellera C

Eur J Cancer. 2025 12 5;233:116166

Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort.

Varnier R, Pérol D, Jacot W, Mailliez A, Diéras V, Dalenc F, Gonçalves A, Levy C, Arnedos M, Frenel JS, Bailleux C, Massard V, Brain E, Sauterey B, Savoye AM, Bosquet L, Thery JC, Petit T, Bachelot T, Grinda T, Ray-Coquard I

ESMO Open. 2025 09 17;10(10):105803

Impact of Electronic Transition and Prefilled Templates on Drug Prescription Compliance: Retrospective Study.

Lambert A, Hombourger B, Salleron J, Chergui F, Vallance C, Nicolas N, Moussouni M, Cherif L, Chenot E, Gavoille C, Massard V

J Med Internet Res. 2025 04 9;27:e57782

Decoding mutational signatures in breast cancer: Insights from a multi-cohort study.

Betz M, Witz A, Dardare J, Michel C, Massard V, Boidot R, Gilson P, Merlin JL, Harlé A

Transl Oncol. 2025 02 4;53:102315

Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort.

Epaillard N, Lusque A, Jacot W, Mailliez A, Bachelot T, Arnedos M, Le Du F, Brain E, Ferrero JM, Massard V, Desmoulins I, Mouret-Reynier MA, Levy C, Gonçalves A, Leheurteur M, Petit T, Filleron T, Bosquet L, Pistilli B, Frenel JS

ESMO Open. 2024 05 3;9(5):103447

Integrated Molecular Characterization of HER2-Low Breast Cancer Using Next Generation Sequencing (NGS).

Merlin JL, Husson M, Sahki N, Gilson P, Massard V, Harlé A, Leroux A

Biomedicines. 2023 11 28;11(12):

First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.

Galvin A, Courtinard C, Bouteiller F, Gourgou S, Dalenc F, Jacot W, Arnedos M, Bailleux C, Dieras V, Petit T, Emile G, Dubray-Longeras P, Frenel JS, Bachelot T, Mailliez A, Brain E, Desmoulins I, Massard V, Patsouris A, Goncalves A, Grinda T, Delaloge S, Bellera C

Eur J Cancer. 2023 11 10;196:113422

Gene Mutations and Liquid Biopsy in ER-Positive Breast Cancers: A Small Step Forward, a Giant Leap for Personalization of Endocrine Therapy?

Betz M, Massard V, Gilson P, Witz A, Dardare J, Harlé A, Merlin JL

Cancers (Basel). 2023 10 27;15(21):

Iron deficiency in patients with cancer: a prospective cross-sectional study.

Luporsi E, Turpin A, Massard V, Morin S, Chauffert B, Carnot A, Cacoub P,

BMJ Support Palliat Care. 2021 Jul 30;:

Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer.

Franczak C, Witz A, Geoffroy K, Demange J, Rouyer M, Husson M, Massard V, Gavoille C, Lambert A, Gilson P, Gambier N, Scala-Bertola J, Merlin JL, Harlé A

PLoS ONE. 2020 ;15(1):e0227294